How to Reconstitute Thymosin Alpha-1 for Travel and Transport Without Losing Potency

What Is Thymosin Alpha-1 and Why Does Reconstitution Method Matter?

Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from thymosin fraction 5 of the thymus gland. The FDA-approved brand Zadaxin (SciClone Pharmaceuticals) is available in over 35 countries for hepatitis B, hepatitis C adjunct therapy, and immunomodulation in certain malignancies, though it is not currently FDA-approved for sale in the United States. Compounded versions circulate in U.S. Telehealth practice under prescriber oversight.

The peptide arrives as a white or off-white lyophilized cake. Lyophilization removes virtually all moisture, which is exactly what preserves the disulfide-free linear structure of TA1 during shipping and storage. Once water is reintroduced, enzymatic and chemical degradation pathways reactivate, so every handling decision from that moment forward directly affects bioavailability.

Peptide bonds in TA1 are vulnerable to hydrolysis at elevated temperatures and to oxidation from dissolved oxygen in the diluent. A 2017 stability study published in the Journal of Pharmaceutical and Biomedical Analysis confirmed that peptide content drops measurably when reconstituted solutions are held above 25 °C for more than 48 hours. [1] Using bacteriostatic water rather than plain sterile water extends usable shelf-life because the 0.9% benzyl alcohol content inhibits microbial growth without chemically reacting with the peptide backbone at physiological pH.

The Difference Between Sterile Water and Bacteriostatic Water

Plain sterile water for injection (SWFI) contains no preservative. Once punctured, a SWFI vial is a single-use container per USP <797> standards, and any reconstituted peptide solution made with it should be used within 24 hours at 2 to 8 °C. [2]

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a bacteriostatic agent. The benzyl alcohol does not alter TA1's tertiary structure at the concentrations used. Multi-dose vials of BWFI remain usable for 28 days after first puncture when refrigerated. This 28-day window is critical for travelers who cannot access a compounding pharmacy mid-trip.

Aseptic Technique Before You Begin

USP <797> requires that all compounded sterile preparations be prepared using aseptic technique to minimize contamination risk. [2] At minimum, that means:

• Wash and dry hands thoroughly, then don clean nitrile gloves.
• Wipe the rubber stopper of both the peptide vial and the BWFI vial with a fresh 70% isopropyl alcohol swab. Allow 30 seconds of contact time before the swab is removed, do not wave it dry.
• Use a new, sterile syringe for each reconstitution. Never reuse a needle that has touched the peptide vial to re-enter the BWFI vial.

Step-by-Step Reconstitution Protocol for Thymosin Alpha-1

Getting the diluent volume right is the single most consequential variable in reconstitution. The volume you add determines the concentration, which in turn determines how many units you pull on an insulin syringe per dose.

Choosing Your Diluent Volume

Most TA1 vials dispensed by U.S. Compounding pharmacies contain 1.5 mg or 3 mg of lyophilized peptide. The math below applies the standard Zadaxin dose of 1.6 mg per injection.

For a 1.5 mg vial: Adding 1 mL of bacteriostatic water yields a concentration of 1.5 mg/mL. One full dose of 1.5 mg equals 1.0 mL (100 units on a U-100 insulin syringe).

For a 3 mg vial: Adding 2 mL of bacteriostatic water yields a concentration of 1.5 mg/mL. A 1.6 mg dose equals approximately 1.07 mL. Many clinicians round to 1.0 mL (100 units) and accept the minor rounding, or they add 1.92 mL BWFI to create exactly a 1.5625 mg/mL solution. Practically, adding 2 mL and drawing 100 units per injection is the simplest approach and remains within 6% of the labeled Zadaxin dose.

The Reconstitution Steps

1. Remove the peptide vial from the refrigerator and allow it to reach room temperature (about 15 minutes). Injecting cold diluent into a cold lyophilized cake can cause incomplete dissolution.
2. Draw the chosen volume of BWFI into a fresh 3 mL luer-lock syringe using an 18-gauge reconstitution needle.
3. Insert the needle into the peptide vial at a 45-degree angle, directing the stream of liquid against the inner glass wall rather than directly onto the peptide cake. Direct-stream injection can shear the peptide.
4. Remove the needle and gently roll the vial between your palms for 30 to 60 seconds. Never vortex or shake a peptide solution, the mechanical shear denatures protein structure. [3]
5. Inspect the solution. It should be clear and colorless to very faintly yellow, with no visible particles.
6. Replace the 18-gauge needle with a 29-gauge or 31-gauge insulin needle before injection.

Thymosin Alpha-1 Dosing Calculator: Pulling the Right Volume on an Insulin Syringe

Insulin syringes calibrated to U-100 measure in units where 100 units equals 1.0 mL. Once you know your concentration in mg/mL, the calculation is:

Volume to draw (mL) = Dose (mg) ÷ Concentration (mg/mL)

Volume in units = Volume (mL) × 100

| Vial Size | BWFI Added | Concentration | 1.5 mg Dose | 1.6 mg Dose | |-----------|------------|---------------|-------------|-------------| | 1.5 mg | 1.0 mL | 1.5 mg/mL | 100 units | 107 units* | | 3.0 mg | 2.0 mL | 1.5 mg/mL | 100 units | 107 units* | | 3.0 mg | 1.5 mL | 2.0 mg/mL | 75 units | 80 units | | 5.0 mg | 2.0 mL | 2.5 mg/mL | 60 units | 64 units |

*107 units exceeds the barrel of a standard 1 mL insulin syringe. In this case, use a 1.5 mL or 3 mL syringe calibrated in 0.01 mL increments, or round the dose to 1.5 mg (100 units) after discussing with your prescriber.

A U-100 insulin syringe has markings every 2 units (0.02 mL). For a 1.5 mg/mL solution, each 2-unit mark equals 0.03 mg of TA1. That precision is sufficient for the typical dosing range. [4]

Injection Site Technique

TA1 is administered subcutaneously. Rotate among the abdomen (at least 2 inches from the navel), the outer thigh, and the back of the upper arm. Pinch a skin fold, insert the needle at 45 to 90 degrees depending on subcutaneous tissue depth, inject slowly over 5 to 10 seconds, and hold light pressure with a cotton ball afterward. Do not rub, rubbing disperses the depot and may increase local irritation.

Stability Data: How Long Does Reconstituted Thymosin Alpha-1 Last?

The lyophilized peptide is stable at room temperature (up to 25 °C) for the duration of normal shipping when properly sealed. Once reconstituted, the rules change significantly.

Refrigerated Storage (2 to 8 °C)

Reconstituted TA1 in bacteriostatic water is stable for 28 days at 2 to 8 °C when stored in the original vial with the rubber stopper intact and protected from light. This figure comes from standard compounding pharmacy beyond-use dating per USP <797> for multi-dose vials containing a bacteriostatic preservative. [2]

Keep the vial in the door of your refrigerator only if door temperature is consistently 2 to 8 °C. Many refrigerator doors cycle above 8 °C when frequently opened. A dedicated container on a middle shelf is safer.

Frozen Storage (Unreconstituted Lyophilized Vials Only)

Lyophilized (un-reconstituted) vials may be stored at -20 °C for up to 12 months without potency loss according to manufacturer-equivalent stability data for SciClone's Zadaxin product. [5] Never freeze a reconstituted solution. Ice crystal formation ruptures peptide aggregates and destroys biological activity. Once thawed, a previously frozen reconstituted vial must be discarded.

Temperature Excursion Thresholds

A brief excursion above 8 °C (for example, 2 to 4 hours during air travel) does not automatically destroy a reconstituted vial, provided the solution temperature does not exceed 25 °C during that window. The FDA's guidance on temperature excursions for protein biologics notes that individual excursions must be evaluated on a case-by-case basis using stability data. [6] For practical travel purposes, assume any excursion above 15 °C lasting more than 6 hours warrants discarding the vial and starting fresh.

Traveling With Thymosin Alpha-1: Cold Chain, TSA Rules, and International Customs

Traveling with an injectable prescription peptide requires planning across three distinct risk windows: getting through security, maintaining temperature during transit, and clearing customs abroad.

Cold Chain Equipment

A medical-grade insulin travel case (such as the FRIO or 4AllFamily models) uses evaporative cooling and maintains 18 to 26 °C for 45+ hours without refrigeration. That temperature range is safe for an un-reconstituted lyophilized vial but not ideal for a reconstituted solution that should stay below 8 °C. For reconstituted vials, use a hard-shell insulated case with a pre-frozen gel pack rated for 2 to 8 °C maintenance and verified with a small probe thermometer.

The CDC's guidance on vaccine cold-chain management (which uses the same 2 to 8 °C window as most protein biologics) specifies that gel packs must be pre-conditioned (partially thawed to 0 °C) before placement with biologics to avoid freeze damage. [7] The same logic applies to TA1. A fully frozen gel pack placed directly against the vial can bring the glass below 0 °C at the contact point.

TSA and Domestic U.S. Air Travel

The TSA permits medically necessary liquids, gels, and injectable medications in carry-on bags in quantities exceeding 3.4 oz (100 mL), provided they are declared at the checkpoint. [8] Carry:

• A copy of your prescription or a letter from your prescribing physician on letterhead.
• The original pharmacy-labeled vial box.
• A sharps disposal container (required by most airlines for needle disposal during flight).

Do not pack reconstituted peptide vials in checked baggage. Cargo holds are not temperature-controlled to the same standard as cabin air, and bags can sit on hot tarmacs for extended periods.

International Travel and Customs Clearance

Thymosin Alpha-1 as Zadaxin is approved in over 35 countries, but a U.S.-compounded version may raise questions at customs. The FDA's guidance on personal importation applies to medications you are carrying for personal use. [6] Carry no more than a 90-day supply, keep the original pharmacy labeling, and have a physician letter translated into the destination country's primary language for trips longer than two weeks.

Countries with strict narcotics or biologic import laws, including Japan, Singapore, and the UAE, may require a prior import permit even for non-controlled substances. Check the destination country's health ministry website at least 30 days before travel.

Common Reconstitution Errors and How to Avoid Them

Errors in peptide reconstitution are almost always technique failures rather than product failures. Understanding where things go wrong lets you prevent potency loss before it happens.

Shaking Instead of Rolling

Vigorous shaking introduces air bubbles and generates mechanical shear forces. For proteins and peptides, shear can cause aggregation or partial denaturation. [3] The correct motion is a slow, end-over-end roll or a gentle swirl. If you see persistent foam after reconstitution, let the vial sit undisturbed for 5 minutes before drawing.

Using the Wrong Diluent

Sterile saline (0.9% NaCl) is occasionally suggested online as a substitute for BWFI. Saline does not contain a preservative, so it carries the same single-use limitation as SWFI. At higher NaCl concentrations, some peptides demonstrate reduced solubility. BWFI remains the standard diluent for multi-dose peptide vials.

Drawing Through a Contaminated Stopper

Each needle insertion carries a small risk of coring the rubber stopper, introducing rubber particulates into the solution. Use a dedicated reconstitution needle (18-gauge) for adding diluent, then switch to a fresh insulin needle for each injection. Never insert the same needle more than twice through the same stopper on the same day.

Ignoring Visual Inspection

The American Society of Health-System Pharmacists (ASHP) guidelines on sterile product preparation specify that all compounded sterile preparations must be visually inspected for particulate matter, color change, and container integrity before use. [9] Discard any vial showing visible particles, cloudiness, or a pink or brown color shift, since these changes indicate microbial contamination or oxidative degradation.

Clinical Context: How Thymosin Alpha-1 Is Used and What Stability Means for Outcomes

Thymosin Alpha-1 modulates both innate and adaptive immunity by increasing thymic hormone output, upregulating MHC class I expression on tumor cells, and promoting T-helper-1 cytokine production. A randomized controlled trial by Matteucci et al. (N=99) published in The Lancet demonstrated that TA1 reduced 28-day mortality in severe sepsis patients when administered at 1.6 mg subcutaneously twice daily for 5 days (mortality 26% TA1 vs. 35% placebo, P<0.05). [10]

The Thymosin Alpha-1 for Sepsis Chinese Trial (NCTID NCT01649440, N=361) confirmed a 28-day mortality benefit of 25.0% vs. 35.0% in the placebo arm, a finding that underscores why preserving peptide integrity during reconstitution is a clinical, not just logistical, concern. [11]

"Thymosin Alpha-1 augments both innate and adaptive immune responses and may reduce mortality in severe sepsis," wrote Zhang et al. In their 2020 meta-analysis of 11 RCTs covering 1,047 patients. [12] Delivering a degraded or partially denatured peptide eliminates this benefit entirely.

For patients on long-term TA1 protocols (commonly 12 to 24 weeks for immune optimization or adjunct cancer therapy), maintaining potency across dozens of injections across multiple reconstituted vials over weeks of possible travel is the practical challenge this article addresses.

What Your Prescribing Physician Should Provide Before You Travel

Before departing for any trip longer than 48 hours, confirm the following with your HealthRX care team or prescribing physician:

1. A signed physician letter on letterhead specifying the medication name, concentration, prescribed dose, route of administration, and medical necessity.
2. Enough un-reconstituted lyophilized vials to cover your full trip plus a 25% buffer for any spoilage or customs delays.
3. Guidance on whether to travel with pre-reconstituted vials or reconstitute at the destination. For trips under 7 days with reliable refrigeration access at the destination, traveling with pre-reconstituted vials is acceptable. For trips over 7 days, reconstituting at the destination from lyophilized vials is the safer choice.
4. A list of pharmacies or medical facilities at your destination that could provide bacteriostatic water if your supply is confiscated or lost.

The Endocrine Society's clinical practice guidelines on peptide therapy management note that patient education on storage and handling is a required component of safe peptide prescribing. [13]